Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Alzheimer's disease and whose blood test results suggest a build-up of a protein called amyloid in the brain (this applies in areas where results can be returned within about 4 weeks of the first visit, and only for those who do not already have a previous brain scan confirming this).
- People whose brain scan (called a PET scan) shows a significant amount of amyloid build-up, measured at a score of 50 or higher on a standard scale called Centiloid.
- People who score 20 or higher on a standard memory and thinking test called the Mini-Mental State Examination (MMSE) at their screening visit.
Who may not be able to join:
- People whose MRI brain scan at screening shows signs that something other than Alzheimer's disease may be causing their memory or thinking problems.
- People who have any serious ongoing health conditions that are not well managed, or any conditions that the trial doctor believes could affect the study results — this includes conditions affecting mental health, the nervous system (other than Alzheimer's), heart, liver, kidneys, stomach and digestion, breathing, hormones, immune system, blood, metabolism, eyes, or skin, as well as a history of abnormal blood test results pointing to a significant illness.
- People who have previously received the study drug ABBV-1758, or who have ever received any anti-amyloid antibody treatment (a type of medication targeting amyloid in the brain).
- People whose MRI brain scan at screening shows certain concerning findings in the brain, including signs of fluid leakage into brain tissue, four or more small bleeds (each no larger than 10mm), any larger bleed (greater than 10mm), any deposits of blood breakdown products on the brain's surface, or significant damage to the brain's white matter.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants Experiencing Adverse Events (AEs); Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results; Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA); Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements; Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters; Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS); Stage A, B, and C: Ch...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.